| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| ln Vitro |
(Arg)9,TAMRA-labeled acetate (1-5 μM; incubation at 37 °C for 3 hours or overnight) showed low permeability to NIH 3T3 mouse embryonic fibroblasts in a dose-dependent manner. At a concentration of 2 μM, there was no statistically significant difference in permeability between 37 °C (active endocytosis plus passive diffusion) and 4 °C (passive diffusion only) [1]. (Arg)9,TAMRA-labeled acetate (5 μM; incubation at 37 °C for 3 hours) showed low permeability to NIH 3T3 mouse embryonic fibroblasts, with sparse punctate distribution of intracellular fluorescence [1]. (Arg)9,TAMRA-labeled acetate (10 μM; incubation at 37 °C for 24 or 48 hours) showed no significant cytotoxicity to NIH 3T3 mouse embryonic fibroblasts [1]. (Arg)9,TAMRA-labeled acetate (2 μM; incubation at 37 °C or 4 °C for 3 hours) showed low permeability to H9 human embryonic stem cells, with no statistically significant difference in permeability between 37 °C and 4 °C, and exhibited a bimodal fluorescence distribution at 37 °C [1]. (Arg)9,TAMRA-labeled acetate (5 μM; incubation at 37 °C for 3 hours) also showed low permeability to H9 human embryonic stem cells, with sparse punctate intracellular fluorescence visible in cell colonies [1]. (Arg)9,TAMRA-labeled acetate (10 μM; incubation at 37 °C for 24 or 48 hours) showed no significant cytotoxicity to H9 human embryonic stem cells [1].
|
|---|---|
| ln Vivo |
(Arg)9,TAMRA-labeled acetate (20 μM; solution; overnight; room temperature) showed no membrane adsorption or internal permeation in demembranous Drosophila embryos/larvae, and no loss of viability or larval transition was observed in the treated hosts [1]. (Arg)9,TAMRA-labeled acetate (20 μM; solution; overnight; room temperature) achieved significant internal permeation in demembranous and dewaxed Drosophila embryos, with viability loss independent of reagent exposure, and all treated hosts remained in the embryonic stage [1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: NIH 3T3 mouse embryonic fibroblasts Tested Concentrations: 10 μM Incubation Duration: 24 hours; 48 hours at 37 °C Experimental Results: No significant difference in viability of NIH 3T3 cells was observed compared with the vector control or other peptides. Cytotoxicity assay [1] Cell Types: H9 human embryonic stem cells Tested Concentrations: 10 μM Incubation Duration: 24 hours; 48 hours at 37 °C Experimental Results: No significant difference in the viability of H9 human embryonic stem cells was observed compared with the vector control or other peptides. |
| Animal Protocol |
Animal/Disease Models:Drosophila melanogaster [1]
Doses: 20 μM Route of Administration:Solution; overnight; room temperature Experimental Results:No adsorption to the outer membrane or penetration into the de-egg-membrane host was observed. It prevented the transition of the treated host to the larval stage. It did not lead to a decrease in the survival rate of the treated host. Significant penetration was achieved in de-egg-membrane and dewaxed hosts. It led to a decrease in the survival rate of the treated host, independent of reagent exposure. All treated hosts remained in the embryonic stage. |
| References |
| Molecular Formula |
C79H130N38O14.XC2H4O2
|
|---|---|
| Molecular Weight |
1836.12 (free base)
|
| Related CAS # |
(Arg)9,TAMRA-labeled
|
| Sequence |
TAMRA-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-ArgTAMRA-RRRRRRRRR
|
| SequenceShortening |
TAMRA-RRRRRRRRR
|
| Appearance |
Brown to reddish brown solid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
